|
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Paraneoplastic Autoantibody Evaluation, CSF
Test CodeCPT Codes
86255 (x9)<br>Restricted Client Code
Includes
If indirect immunofluorescence assay (IFA) pattern suggests antiglial nuclear antibody-1 (AGNA-1) antibody, then AGNA-1 immunoblot is performed at an additional charge. (CPT code(s): 84182)
If IFA pattern suggests antineuronal nuclear antibodies (ANNA)-1 antibody, then ANNA-1 immunoblot is performed at an additional charge. (CPT code(s): 84182)
If IFA pattern suggests ANNA-2 antibody, then ANNA-2 immunoblot is performed at an additional charge. (CPT code(s): 84182)
If IFA pattern suggests Purkinje cytoplasmic antibody (PCA)-1 antibody, then PCA-1 immunoblot is performed at an additional charge. (CPT code(s): 84182)
If IFA pattern suggests PCA-Tr antibody, then PCA-Tr immunoblot is performed at an additional charge. (CPT code(s): 84182)
If IFA patterns suggest collapsin response-mediator protein (CRMP)-5-IgG, then CRMP-5-IgG Western blot is performed at an additional charge. (CPT code(s): 84182)
If IFA patterns suggest glutamic acid decarboxylase 65 (GAD65) antibody, then GAD65 antibody radioimmunoassay (RIA) is performed at an additional charge. (CPT code(s): 86341)
If IFA patterns suggest neuronal voltage-gated potassium channel-complex (VGKC) autoantibody, then VGKC-complex antibody RIA is performed at an additional charge (CPT code(s): 83519)
If VGKC-complex antibody RIA result is greater than 0.00 nmol/L, then leucine-rich, glioma inactivated 1 (LGI1)-IgG cell-binding assay (CBA) and contactin-associated protein-like 2 (CASPR2)-IgG CBA are performed at an additional charge (CPT code(s): 86255(x2))
If IFA patterns suggest amphiphysin antibody, then amphiphysin immunoblot is performed at an additional charge. (CPT code(s): 84182)
If IFA pattern suggests N-methyl-D-aspartate (NMDA)-receptor, then NMDA-receptor antibody CBA and/or NMDA-receptor antibody IFA titer is performed at an additional charge. (CPT code(s): 86256)
If IFA pattern suggests alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA)-receptor, then AMPA-Receptor antibody CBA and/or AMPA-receptor antibody IFA titer is performed at an additional charge. (CPT code(s): 86256)
If IFA pattern suggests gamma-aminobutyric acid B (GABA-B)-receptor, then GABA-B-receptor antibody CBA and/or GABA-B-Receptor antibody IFA titer is performed at an additional charge. (CPT code(s): 86256)
If IFA pattern suggests dipeptidyl-peptidase-like protein-6 antibody (DPPX), then DPPX antibody CBA and DPPX antibody IFA titer is performed at an additional charge. (CPT code(s): 86255, 86256)
If IFA pattern suggests metabotropic glutamate receptor 1 (mGluR1), then mGluR1 antibody CBA and mGluR1 antibody IFA titer is performed at an additional charge. (CPT code(s): 86255, 86256).
Preferred Specimen
Minimum Volume
Instructions
Forms: If not ordering electronically, submit a Neurology Specialty Testing Client Test Request Form (Supply T732) with the specimen.
Please note: In patients with a history of tobacco use or other lung cancer risk. or if thymoma is suspected, PAVAL/Paraneoplastic Autoantibody Evaluation, Serum is also recommended.
Transport Temperature
Specimen Stability
Refrigerated: 28 days
Frozen: 28 days
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Methodology
Western Blot • Cell-binding Assay (CBA) • Indirect Immunofluorescence Assay • Immunoblot • Radioimmunoassay
FDA Status
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.
Setup Schedule
Reference Range
Clinical Significance